Drugs / MK-1708
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06647628 | Nov 2024 → Mar 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06586606 | Oct → Dec 2024 | Alzheimer disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-1708 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06647628 ↗ |
| Route | Oral | “Oral administration” NCT06586606 ↗ |